secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001438533-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025
----------------------------------------------------------------

- Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).
- Plans to submit sNDA for FILSPARI in FSGS around end of Q1 2025, based on Phase 3 DUPLEX and Phase 2 DUET.
- FDA granted full approval for IgAN in Sept 2024; received 693 new patient start forms in Q4.
- Pegtibatinase Phase 3 HARMONY restart expected in 2026 after manufacturing scale-up improvements.
- Cash and marketable securities $370.7M as of Dec 31, 2024, including $134.7M from Nov stock offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/0001438533-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/tvtx-20250220.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer